利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.013 秒)

    Compounds and methods for the treatment of vascular disease
    1.
    发明授权
    Compounds and methods for the treatment of vascular disease 有权
    用于治疗血管疾病的化合物和方法

    公开(公告)号：US08809497B2

    公开(公告)日：2014-08-19

    申请号：US12808947

    申请日：2008-12-18

    申请人： Johan Frostegard ,  Knut Pettersson

    发明人： Johan Frostegard ,  Knut Pettersson

    IPC分类号： C07K14/00

    CPC分类号： A61K38/1709 ,  A61K9/0019 ,  A61K31/4365 ,  A61K31/616 ,  A61K38/49 ,  A61K45/06 ,  A61K47/60 ,  A61K2300/00

    摘要： The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.

    摘要翻译： 本发明涉及一种治疗血管功能障碍，减少缺血性疼痛和/或治疗血管疾病的方法，包括向需要这种治疗的患者施用治疗有效量的膜联蛋白A5或其功能类似物或变体。 血管功能障碍，缺血性疼痛和/或血管疾病可能与内皮介导的血管扩张受损，eNOS活性降低和/或NO生物利用度降低有关。 患者可能患有选自心绞痛，缺血性心脏病，外周动脉疾病，收缩期高血压，偏头痛，2型糖尿病和勃起功能障碍的疾病。

    ANTIBODIES AGAINST PHOSPHORYLCHOLINE
    2.
    发明申请
    ANTIBODIES AGAINST PHOSPHORYLCHOLINE 有权

    公开(公告)号：US20140178410A1

    公开(公告)日：2014-06-26

    申请号：US14237035

    申请日：2012-08-08

    申请人： Knut Pettersson ,  Ola Camber ,  Dan Sexton ,  Andrew E. Nixon

    发明人： Knut Pettersson ,  Ola Camber ,  Dan Sexton ,  Andrew E. Nixon

    IPC分类号： C07K16/44

    CPC分类号： C07K16/44 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/70 ,  C07K2317/92

    摘要： The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25; a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26.

    Antibodies against phosphorylcholine
    3.
    发明授权
    Antibodies against phosphorylcholine 有权

    公开(公告)号：US09803028B2

    公开(公告)日：2017-10-31

    申请号：US14237035

    申请日：2012-08-08

    申请人： Knut Pettersson ,  Ola Camber ,  Dan Sexton ,  Andrew E. Nixon

    发明人： Knut Pettersson ,  Ola Camber ,  Dan Sexton ,  Andrew E. Nixon

    IPC分类号： C07K16/44 ,  A61K39/00

    CPC分类号： C07K16/44 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/70 ,  C07K2317/92

    摘要： The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25; a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26.

    Methods for treating restenosis using annexin A5
    4.
    发明授权
    Methods for treating restenosis using annexin A5 有权
    使用膜联蛋白A5治疗再狭窄的方法

    公开(公告)号：US09295716B2

    公开(公告)日：2016-03-29

    申请号：US12918709

    申请日：2009-02-20

    申请人： Knut Pettersson ,  Johan Frostegard ,  Ola Camber

    发明人： Knut Pettersson ,  Johan Frostegard ,  Ola Camber

    IPC分类号： A61K38/17 ,  A61K38/49 ,  A61L31/16 ,  C07K14/47 ,  A61K38/00

    CPC分类号： A61K38/17 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/49 ,  A61K45/06 ,  A61L27/3625 ,  A61L27/54 ,  A61L31/16 ,  A61L33/0011 ,  A61L2300/252 ,  A61L2300/42 ,  C07K14/4721 ,  A61K2300/00

    摘要： A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analog or variant thereof, and a method of making such a stent.

    摘要翻译： 一种预防或治疗再狭窄的方法，包括向需要这种治疗的患者施用治疗有效量的膜联蛋白A5或其功能类似物或变体。 一种用于治疗患者狭窄的方法，其包括与施用治疗有效量的膜联蛋白A5或其功能类似物或变体一起进行治疗狭窄的干预。 一种药物组合物，其包含治疗有效量的膜联蛋白A5或其功能类似物或变体，用于预防或治疗再狭窄。 药物洗脱支架，其中药物是膜联蛋白A5或其功能性类似物或变体，以及制备这种支架的方法。

    THERAPEUTIC AND PROPHYLACTIC METHODS, USES AND COMPOSITIONS COMPRISING ANEXIN A5
    5.
    发明申请
    THERAPEUTIC AND PROPHYLACTIC METHODS, USES AND COMPOSITIONS COMPRISING ANEXIN A5 审中-公开
    治疗和预防方法，使用和组合包含ANEXIN A5

    公开(公告)号：US20140037614A1

    公开(公告)日：2014-02-06

    申请号：US14110176

    申请日：2012-04-05

    申请人： Knut Pettersson

    发明人： Knut Pettersson

    IPC分类号： A61K38/17 ,  A61K45/06

    CPC分类号： A61K38/1709 ,  A61K31/4365 ,  A61K31/616 ,  A61K38/49 ,  A61K45/06 ,  C07K14/4728 ,  A61K2300/00

    摘要： The present invention provides a method for the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery, comprising administering a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof to a patient in need of such treatment, Also provided is a pharmaceutical composition comprising a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof for use in the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery.

    摘要翻译： 本发明提供了一种用于预防和/或减少外科手术后的术后并发症的方法，例如血管手术后的并发症，特别是外周血管手术，其包括给予治疗有效量的膜联蛋白（A5）或功能类似物 还提供了包含治疗有效量的膜联蛋白（A5）或其功能类似物或变体的药物组合物，用于预防和/或减少手术或术后并发症 以下手术干预，如血管手术后的并发症，特别是外周血管手术。

    Compounds and Methods for the Prevention or Treatment of Restenosis
    8.
    发明申请
    Compounds and Methods for the Prevention or Treatment of Restenosis 有权
    预防或治疗再狭窄的化合物和方法

    公开(公告)号：US20100331970A1

    公开(公告)日：2010-12-30

    申请号：US12918709

    申请日：2009-02-20

    申请人： Knut Pettersson ,  Johan Frostegard ,  Ola Camber

    发明人： Knut Pettersson ,  Johan Frostegard ,  Ola Camber

    IPC分类号： A61F2/82 ,  A61K38/16 ,  A61K38/45 ,  A61K38/43 ,  A61K38/17 ,  A61L33/00

    CPC分类号： A61K38/17 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/49 ,  A61K45/06 ,  A61L27/3625 ,  A61L27/54 ,  A61L31/16 ,  A61L33/0011 ,  A61L2300/252 ,  A61L2300/42 ,  C07K14/4721 ,  A61K2300/00

    摘要： A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent.

    摘要翻译： 一种预防或治疗再狭窄的方法，包括向需要这种治疗的患者施用治疗有效量的膜联蛋白A5或其功能类似物或变体。 一种用于治疗患者狭窄的方法，其包括与施用治疗有效量的膜联蛋白A5或其功能类似物或变体一起进行治疗狭窄的干预。 一种药物组合物，其包含治疗有效量的膜联蛋白A5或其功能类似物或变体，用于预防或治疗再狭窄。 药物洗脱支架，其中药物是膜联蛋白A5或其功能类似物或变体，以及制备这种支架的方法。

    ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES
    9.
    发明申请
    ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES 有权
    抗体与磷酸胆碱（PC）和/或PC结合

    公开(公告)号：US20140193413A1

    公开(公告)日：2014-07-10

    申请号：US14235970

    申请日：2012-08-08

    申请人： Knut Pettersson ,  Ola Camber ,  Dan Sexton ,  Andrew E. Nixon

    发明人： Knut Pettersson ,  Ola Camber ,  Dan Sexton ,  Andrew E. Nixon

    IPC分类号： C07K16/44

    CPC分类号： C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92

    摘要： The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.

    摘要翻译： 本公开涉及能够结合磷酸胆碱和/或磷酸胆碱缀合物的抗体或抗体片段，其中所述抗体或抗体片段包含可变重链（VH）结构域和/或可变轻链（VL）结构域，以及 其中（a）VH结构域包含选自以下的互补决定区（CDR）：与SEQ ID NO：7的序列具有同一性的CDR1序列; 与SEQ ID NO：8的序列具有同一性的CDR2序列; 和与SEQ ID NO：9或10的序列具有同一性的CDR3序列; 和/或（b）所述VL结构域包含选自以下的CDR：与SEQ ID NO：11的序列具有同一性的CDR4序列; 与SEQ ID NO：12的序列具有同一性的CDR5序列; 与SEQ ID NO：13的序列具有同一性的CDR6序列。

    Compounds and Methods for the Treatment of Vascular Disease
    10.
    发明申请
    Compounds and Methods for the Treatment of Vascular Disease 有权
    化合物和治疗血管疾病的方法

    公开(公告)号：US20100291064A1

    公开(公告)日：2010-11-18

    申请号：US12808947

    申请日：2008-12-18

    申请人： Johan Frostegard ,  Knut Pettersson

    发明人： Johan Frostegard ,  Knut Pettersson

    IPC分类号： A61K38/49 ,  A61K38/17 ,  A61K38/43 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P25/06

    CPC分类号： A61K38/1709 ,  A61K9/0019 ,  A61K31/4365 ,  A61K31/616 ,  A61K38/49 ,  A61K45/06 ,  A61K47/60 ,  A61K2300/00

    摘要： The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.

    摘要翻译： 本发明涉及一种治疗血管功能障碍，减少缺血性疼痛和/或治疗血管疾病的方法，包括向需要这种治疗的患者施用治疗有效量的膜联蛋白A5或其功能类似物或变体。 血管功能障碍，缺血性疼痛和/或血管疾病可能与内皮介导的血管扩张受损，eNOS活性降低和/或NO生物利用度降低有关。 患者可能患有选自心绞痛，缺血性心脏病，外周动脉疾病，收缩期高血压，偏头痛，2型糖尿病和勃起功能障碍的疾病。